Kabra Drugs Stock Screener | Share Price & Fundamental Analysis
KABRADG
Pharmaceuticals
Screen Kabra Drugs share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹28.43
▼
-0.62 (-2.13%)
Market Cap
₹71.05 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
2.70
EPS (TTM)
₹-0.99
Dividend Yield
-
Debt to Equity
0.08
52W High
₹31.90
52W Low
₹10.06
Operating Margin
1.00%
Profit Margin
3.57%
Revenue (TTM)
₹28.00
EBITDA
₹2.00
Net Income
₹1.00
Total Assets
₹25.00
Total Equity
₹25.00
Kabra Drugs Share Price History - Stock Screener Chart
Screen KABRADG historical share price movements with interactive charts. Analyze price trends and patterns.
Kabra Drugs Company Profile - Fundamental Screener
Screen Kabra Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for KABRADG shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE323K01017
Kabra Drugs Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen KABRADG balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 25 | 5 | 1 | 1 | 1 | 1 | 2 | 2 | 6 | 9 |
| Current Assets | 25 | 5 | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 6 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Liabilities | ||||||||||
| Total Liabilities | 25 | 5 | 1 | 1 | 1 | 1 | 2 | 2 | 6 | 9 |
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 25 | 1 | -1 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Share Capital | 24 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves & Surplus | 1 | -6 | -5 | -5 | -5 | -4 | -4 | -4 | -2 | -2 |
Screen KABRADG income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 10 | 8 |
| Expenses | 26 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 7 | 9 | 8 |
| EBITDA | 2 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | -1 | 1 | 1 | 0 |
| Operating Profit % | 1.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -57.00% | 6.00% | 5.00% | 5.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 | 0 |
| EPS | 0.20 | -0.99 | -1.68 | -0.77 | -0.42 | -0.41 | -0.14 | -0.38 | -5.37 | 0.30 | 0.06 | 0.16 |
Kabra Drugs Cash Flow Screener - Liquidity Fundamentals
Screen KABRADG cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Financing Activities | 23 | 3 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
| Net Cash Flow | 19 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Screen KABRADG shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 95.94% | 95.61% | 95.00% | 95.73% | 95.85% | 96.19% | 96.12% | 95.97% |
| Other Holding | 4.06% | 4.39% | 5.00% | 4.27% | 4.15% | 3.81% | 3.88% | 4.03% |
| Shareholder Count | 7,435 | 7,449 | 8,098 | 7,364 | 7,336 | 7,367 | 7,343 | 7,424 |
Kabra Drugs Dividend Screener - Share Yield Analysis
Screen KABRADG dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Kabra Drugs Index Membership - Market Screener Classification
Screen KABRADG by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Kabra Drugs Market Events Screener - Corporate Actions
Screen KABRADG market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -1.53% | ||
| Change Of Name | NA | 0.00% | ||
| Annual General Meeting | NA | 4.94% | ||
| 2025-12-26 | 2025-12-26 | Extraordinary General Meeting | NA | -0.91% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 7.48% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | 1.97% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 0.00% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | 4.97% |
| 2025-01-02 | 2025-01-02 | Extraordinary General Meeting | NA | 4.90% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | 4.92% |
| 2024-02-17 | 2024-02-17 | Extraordinary General Meeting | NA | 10.13% |
Kabra Drugs Competitors Screener - Peer Comparison
Screen KABRADG competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,734 | 39.35 | 54,729 | 9.71% | 10,980 | 39.06 |
| Divis Laboratories | 168,851 | 68.64 | 9,712 | 18.67% | 2,191 | 44.96 |
| Torrent Pharmaceuticals | 129,357 | 60.42 | 11,539 | 6.99% | 1,911 | 59.35 |
| Cipla | 120,557 | 22.17 | 28,410 | 7.12% | 5,291 | 42.76 |
| Dr Reddys Laboratories | 105,645 | 18.42 | 33,741 | 16.73% | 5,725 | 49.97 |
| Lupin | 95,023 | 21.87 | 22,910 | 13.74% | 3,306 | 50.10 |
| Zydus Life Science | 90,707 | 18.03 | 23,511 | 18.55% | 4,615 | 34.06 |
| Mankind Pharma | 88,846 | 50.11 | 12,744 | 20.90% | 2,007 | 40.67 |
| Aurobindo Pharma | 68,901 | 20.16 | 32,346 | 9.43% | 3,484 | 46.33 |
| Alkem Laboratories | 65,390 | 26.89 | 13,458 | 3.70% | 2,216 | 37.45 |
Kabra Drugs Company Announcements - News Screener
Screen KABRADG latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-08 | Closure of Trading Window | View |
| 2026-01-05 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | View |
| 2026-01-04 | Shareholder Meeting / Postal Ballot-Outcome of EGM | View |
| 2025-12-31 | Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-12-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-03 | Submission Of Notice Of Extra Ordinary General Meeting Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulations 2015 | View |
| 2025-11-28 | Appointment Of Secretarial Auditor Of The Company | View |
| 2025-11-28 | Resignation Of Secretarial Auditor Of The Company | View |
| 2025-11-28 | Board Meeting Outcome for Outcome Of Board Meeting Held On 28Th November 2025 As Per Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | View |
| 2025-11-20 | Board Meeting Intimation for Intimation Of Board Meeting | View |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-13 | Financial Results For The Quarter Ended 30 Th September 2025 Under Regulation 33 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 | View |
| 2025-11-13 | Board Meeting Outcome for Outcome Of Board Meeting Held On 13 Th November 2025 As Per Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | View |
| 2025-11-05 | Board Meeting Intimation for Intimation Of Board Meeting | View |
| 2025-10-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-09 | Announcement under Regulation 30 (LODR)-Change in Directorate | View |
| 2025-10-08 | Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) | View |
| 2025-10-08 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-10-08 | Announcement under Regulation 30 (LODR)-Change in Directorate | View |
| 2025-10-08 | Announcement under Regulation 30 (LODR)-Resignation of Director | View |